kais1. Eur J Cancer. 2017 Aug;81:45-55. doi: 10.1016/j.ejca.2017.05.005. Epub 2017 Jun
8.

ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage
Hodgkin Lymphoma with risk factors: Results of the European Organisation for
Research and Treatment of Cancer (EORTC)-Groupe d'Étude des Lymphomes de l'Adulte
(GELA) H9-U intergroup randomised trial.

Fermé C(1), Thomas J(2), Brice P(3), Casasnovas O(4), Vranovsky A(5), Bologna
S(6), Lugtenburg PJ(7), Bouabdallah R(8), Carde P(1), Sebban C(9), Eghbali H(10),
Salles G(11), van Imhoff GW(12), Thyss A(13), Noordijk EM(14), Reman O(15),
Lybeert MLM(16), Janvier M(17), Spina M(18), Audhuy B(19), Raemaekers JMM(20),
Delarue R(21), Anglaret B(22), de Weerdt O(23), Marjanovic Z(24), Tersteeg
RJHA(25), de Jong D(26), Brière J(3), Henry-Amar M(27); European Organisation for
Research and Treatment of Cancer Lymphoma Group, and; Groupe d'Étude des
Lymphomes de l'Adulte.

Author information: 
(1)Gustave Roussy, 114 Rue Édouard Vaillant, 94805 Villejuif Cedex, France.
(2)University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium.
(3)Centre Hospitalier Universitaire, Hôpital Saint-Louis, 1 Avenue Claude
Vellefaux, 75010 Paris, France.
(4)Centre Hospitalier Universitaire, Hôpital du Bocage, 1 Boulevard Jeanne d'Arc,
21000 Dijon, France.
(5)National Cancer Institute, Klenova 1, 83310 Bratislava, Slovakia.
(6)Centre Hospitalier Universitaire de Nancy, Hôpital Brabois, Rue du Morvan,
54511 Vandœuvre-lès-Nancy, France.
(7)Erasmus Medical Center, 's-Gravendijkwal 230, 3015 CE Rotterdam, The
Netherlands.
(8)Institut Paoli Calmettes, 232 Boulevard Sainte-Marguerite, BP156, 13273
Marseille Cedex 09, France.
(9)Centre Léon Bérard, 28 Rue Laennec, 69373 Lyon Cedex 8, France.
(10)Institut Bergonié, 229 Cours de l'Argonne, CS 61283, 33076 Bordeaux Cedex,
France.
(11)Centre Hospitalier Lyon Sud, Chemin du Grand Revoyet, 69310 Pierre-Bénite,
France.
(12)University Medical Center Groningen, Hanzeplein 1, 9713 GZ Groningen, P.O.
Box 30.001, 9700 RB Groningen, The Netherlands.
(13)Centre Antoine Lacassagne, 33 Avenue de Valombrose, 06189 Nice Cedex 2,
France.
(14)Leiden University Medical Center, P.O. Box 9600, 2300 RC Leiden, The
Netherlands.
(15)Centre Hospitalier Universitaire, Avenue de la Côte de Nacre, 14033 Caen,
France.
(16)Catharina Ziekenhuis, Michelangelolaan 2, 5623 EJ Eindhoven, The Netherlands.
(17)Institut Curie-Hôpital René-Huguenin, 35 Rue Dailly, 92210 Saint-Cloud,
France.
(18)Centro di Riferimento Oncologico, Via Franco Gallini, 2, 33081 Aviano, PN,
Italy.
(19)Hôpitaux Civils de Colmar, Hôpital Pasteur, 39 Avenue de la Liberté, 68024
Colmar Cedex, France.
(20)Radboud University Nijmegen Medical Center, Geert Grooteplein Zuid 10, 6525
GA Nijmegen, The Netherlands.
(21)Centre Hospitalier Universitaire, Hôpital Necker, 149 Rue de Sèvres, 75015
Paris, France.
(22)Centre Hospitalier de Valence, 179 Avenue du Maréchal Juin, 26953 Valence,
France.
(23)St. Antonius Ziekenhuis Nieuwegein, Koekoekslaan 1, 3435 CM Nieuwegein, The
Netherlands.
(24)Centre Hospitalier Universitaire, Hôpital Saint-Antoine, 184 Rue du faubourg 
Saint-Antoine, 75012 Paris, France.
(25)University Medical Center Utrecht, Heidelberglaan 100, 3584 CX Utrecht, The
Netherlands.
(26)VU University Medical Center, Department of Pathology, De Boelelaan 1117,
1081HV Amsterdam, The Netherlands.
(27)Centre de Traitement des Données du Cancéropôle Nord-Ouest, Centre François
Baclesse, 3 Avenue Général Harris, 14076 Caen Cedex 05, France. Electronic
address: m.henry.amar@baclesse.unicancer.fr.

PURPOSE: For early-stage Hodgkin lymphoma (HL), optimal chemotherapy regimen and 
the number of cycles to be delivered remain to settle down. The H9-U trial
compared three modalities of chemotherapy followed by involved-field radiotherapy
(IFRT) in patients with stage I-II HL and risk factors (NCT00005584).
PATIENTS AND METHODS: Patients aged 15-70 years with untreated supradiaphragmatic
HL with at least one risk factor (age ? 50, involvement of 4-5 nodal areas,
mediastinum/thoracic ratio ? 0.35, erythrocyte sedimentation rate (ESR) ? 50
without B-symptoms or ESR ? 30 and B-symptoms) were eligible for the randomised, 
open label, multicentre, non-inferiority H9-U trial. The limit of non-inferiority
was set at 10% for the difference between 5-year event-free survival (EFS)
estimates. From October 1998 to September 2002, 808 patients were randomised to
receive either the control arm 6-ABVD-IFRT (n = 276), or one of the two
experimental arms: 4-ABVD-IFRT (n = 277) or 4-BEACOPPbaseline-IFRT (n = 255).
RESULTS: Results in the 4-ABVD-IFRT (5-year EFS, 85.9%) and the
4-BEACOPPbaseline-IFRT (5-year EFS, 88.8%) were not inferior to 6-ABVD-IFRT
(5-year EFS, 89.9%): difference of 4.0% (90%CI, -0.7%-8.8%) and of 1.1%
(90%CI,-3.5%-5.6%) respectively. The 5-year overall survival estimates were 94%, 
93%, and 93%, respectively. Patients treated with combined modality treatment
chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin,
vincristine (Oncovin), cyclophosphamide, procarbazine, etoposide and prednisone
(BEACOPP)baseline more often developed serious adverse events requiring
supportive measures and hospitalisation compared with patients receiving the
chemotherapeutic regimen comprising doxorubicin (Adriamycin), bleomycin,
vinblastine and dacarbazine (ABVD).
CONCLUSIONS: The trial demonstrates that 4-ABVD followed by IFRT yields high
disease control in patients with early-stage HL and risk factors responding to
chemotherapy. Although non-inferior in terms of efficacy, four cycles of
BEACOPPbaseline were more toxic than four or six cycles of ABVD.

Copyright © 2017 Elsevier Ltd. All rights reserved.

DOI: 10.1016/j.ejca.2017.05.005 
PMID: 28601705  [Indexed for MEDLINE]
